Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

NCT05678673 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

317

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Clear Cell Renal Cell Carcinoma

Interventions

DRUG: XL092
DRUG: Nivolumab
DRUG: Sunitinib Malate

Sponsor

Exelixis